Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 530233 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Auro Laboratories Ltd is a average quality company.
The key valuation ratios of Auro Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Auro Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 8% | 8% | 6.5% | 19.6% | 18.5% | 15.4% | 25.2% | 7.5% | 5.7% | 13.4% | - |
| Value Creation Index ⓘ | -0.4 | -0.4 | -0.5 | 0.4 | 0.3 | 0.1 | 0.8 | -0.5 | -0.6 | 0.0 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 32.7 | 27.9 | 35.5 | 40.8 | 46.8 | 43.8 | 54.3 | 50.9 | 52.9 | 53.6 | 54 |
| Sales YoY Gr. | - | -14.5% | 27.1% | 15% | 14.8% | -6.5% | 23.9% | -6.2% | 4% | 1.4% | - |
| Adj EPS ⓘ | 1.1 | 1 | 0.8 | 5.2 | 6.1 | 5.5 | 10.9 | 3.7 | 3 | 10.9 | 12.5 |
| YoY Gr. | - | -3.7% | -24.3% | 561.5% | 18% | -9% | 96.2% | -65.7% | -20.1% | 265.4% | - |
| BVPS (₹) ⓘ | 12.4 | 13.8 | 15.1 | 20.8 | 27.9 | 34.5 | 45.9 | 50.6 | 54.9 | 67.3 | 67.3 |
| Adj Net Profit ⓘ | 0.7 | 0.6 | 0.5 | 3.2 | 3.8 | 3.5 | 6.8 | 2.3 | 1.9 | 6.8 | 8 |
| Cash Flow from Ops. ⓘ | -0.8 | 7.9 | 5.9 | 4.8 | 6.9 | 9.3 | 12.8 | -6.6 | 3.3 | 18.8 | - |
| Debt/CF from Ops. ⓘ | -21 | 1.6 | 1.7 | 1.9 | 1.2 | 0.3 | 0.3 | -2.1 | 2 | 1.4 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.7% | 2.8% | -0.4% | 1.4% | ||||
| Adj EPS ⓘ | 29.4% | 12.3% | 0.1% | 265.4% | ||||
| BVPSⓘ | 20.7% | 19.2% | 13.7% | 22.7% | ||||
| Share Price | 42.3% | 29.8% | 24% | 130.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.2 | 7.9 | 5.4 | 28.7 | 25 | 17.7 | 27.1 | 7.7 | 5.7 | 17.8 | 18.6 |
| Op. Profit Mgn % ⓘ | 9 | 10 | 12.5 | 15.6 | 14.9 | 14.3 | 20.7 | 9.1 | 8.3 | 19.9 | 19.9 |
| Net Profit Mgn % ⓘ | 2.1 | 2.3 | 1.4 | 7.9 | 8.1 | 7.9 | 12.5 | 4.6 | 3.5 | 12.7 | 14.5 |
| Debt to Equity ⓘ | 2.1 | 1.5 | 1.1 | 0.7 | 0.5 | 0.2 | 0.1 | 0.4 | 0.2 | 0.6 | 0.4 |
| Working Cap Days ⓘ | 173 | 188 | 124 | 119 | 112 | 112 | 87 | 139 | 202 | 212 | 117 |
| Cash Conv. Cycle ⓘ | 93 | 91 | 39 | 29 | 37 | 39 | 20 | 58 | 84 | 81 | 49 |
Return on Equity has increased versus last 3 years average to 18.60%
Sales growth has been subdued in last 3 years -0.38%
Net Profit has been subdued in last 3 years 0.06%
Sales growth is not so good in last 4 quarters at 0.50%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 12.5 | - |
| TTM Sales (₹ Cr.) | 53.6 | - |
| BVPS (₹.) ⓘ | 67.3 | - |
| Reserves (₹ Cr.) ⓘ | 36 | - |
| P/BV ⓘ | 3.12 | - |
| PE ⓘ | 16.81 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 75.12 / 307.20 |
| All Time Low / High (₹) | 0.70 / 307.20 |
| Market Cap (₹ Cr.) | 131 |
| Equity (₹ Cr.) | 6.2 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 42.1 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 28 | 35 | 41 | 47 | 44 | 54 | 51 | 53 | 54 |
| Operating Expenses ⓘ | 30 | 25 | 31 | 34 | 40 | 38 | 43 | 46 | 49 | 43 |
| Manufacturing Costs | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | 4 |
| Material Costs | 23 | 18 | 22 | 25 | 29 | 24 | 29 | 33 | 36 | 27 |
| Employee Cost | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Other Costs ⓘ | 2 | 3 | 3 | 4 | 5 | 6 | 7 | 6 | 6 | 8 |
| Operating Profit ⓘ | 3 | 3 | 4 | 6 | 7 | 6 | 11 | 5 | 4 | 11 |
| Operating Profit Margin (%) | 9.0% | 10.0% | 12.5% | 15.6% | 14.9% | 14.3% | 20.7% | 9.1% | 8.3% | 19.9% |
| Other Income ⓘ | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Interest ⓘ | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 1 | 3 | 5 | 6 | 6 | 11 | 4 | 3 | 10 |
| Tax ⓘ | 0 | 0 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 3 |
| Profit After Tax | 1 | 1 | 1 | 4 | 4 | 4 | 7 | 3 | 2 | 8 |
| PAT Margin (%) | 2.5% | 3.2% | 2.3% | 8.7% | 9.4% | 9.3% | 13.2% | 5.6% | 4.6% | 14.5% |
| Adjusted EPS (₹) | 1.3 | 1.4 | 1.3 | 5.7 | 7.1 | 6.5 | 11.5 | 4.6 | 3.9 | 12.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 8 | 9 | 9 | 13 | 17 | 21 | 29 | 32 | 34 | 42 |
| Share Capital ⓘ | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves ⓘ | 1 | 2 | 3 | 7 | 11 | 15 | 22 | 25 | 28 | 36 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 16 | 13 | 10 | 9 | 8 | 3 | 3 | 13 | 6 | 26 |
| Long Term Debt | 8 | 7 | 10 | 6 | 5 | 3 | 2 | 2 | 2 | 18 |
| Short Term Debt | 9 | 5 | 0 | 3 | 4 | 0 | 1 | 12 | 4 | 8 |
| Trade Payables | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 5 | 11 | 6 |
| Others Liabilities ⓘ | 1 | 1 | 3 | 3 | 3 | 3 | 5 | 5 | 4 | 11 |
| Total Liabilities ⓘ | 29 | 26 | 27 | 30 | 33 | 32 | 42 | 55 | 56 | 86 |
Fixed Assets | ||||||||||
| Gross Block | 15 | 15 | 20 | 21 | 23 | 24 | 24 | 25 | 25 | 36 |
| Accumulated Depreciation | 6 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| Net Fixed Assetsⓘ | 10 | 9 | 13 | 13 | 15 | 14 | 14 | 14 | 13 | 22 |
| CWIP ⓘ | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 4 | 8 | 33 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 6 | 4 | 1 | 1 | 3 | 4 | 3 | 4 | 12 | 8 |
| Trade Receivables | 8 | 5 | 8 | 8 | 9 | 6 | 7 | 14 | 12 | 13 |
| Cash Equivalents | 0 | 1 | 1 | 2 | 4 | 6 | 15 | 12 | 2 | 2 |
| Others Assetsⓘ | 4 | 3 | 4 | 4 | 3 | 2 | 4 | 7 | 9 | 8 |
| Total Assets ⓘ | 29 | 26 | 27 | 30 | 33 | 32 | 42 | 55 | 56 | 86 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1 | 8 | 6 | 5 | 7 | 9 | 13 | -7 | 3 | 19 |
| PBT ⓘ | 1 | 1 | 3 | 5 | 6 | 6 | 11 | 4 | 3 | 10 |
| Adjustment ⓘ | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 |
| Changes in Working Capital ⓘ | -4 | 5 | 2 | -1 | -1 | 2 | 1 | -12 | -2 | 6 |
| Tax Paid ⓘ | 0 | 0 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | -1 | -2 | -2 | -2 | -3 | -2 | -4 | -5 | -5 | -39 |
| Capex | -1 | -3 | 0 | -2 | -2 | -1 | 0 | -5 | -4 | -36 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | -2 | 0 | -2 | -2 | -3 | -1 | -1 | -3 |
| Cash Flow From Financing Activityⓘ | 1 | -5 | -4 | -2 | -2 | -6 | 0 | 10 | -8 | 19 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | -1 | 0 | -1 | -1 | 0 | 0 | 1 | 17 |
| Interest Paid ⓘ | -2 | -2 | -1 | -1 | -1 | -1 | 0 | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 2 | -4 | -2 | -1 | 0 | -4 | 0 | 11 | -8 | 3 |
| Net Cash Flow ⓘ | -1 | 0 | 0 | 1 | 2 | 2 | 9 | -2 | -10 | -1 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 11.01 | 10.83 | 9.06 | 31.53 | 28.95 | 20.84 | 28.67 | 9.47 | 7.43 | 20.46 |
| ROCE (%) | 10.76 | 11.21 | 20.24 | 28.65 | 29.12 | 24.8 | 38.88 | 12.2 | 9.92 | 20.37 |
| Asset Turnover Ratio | 1.23 | 1.08 | 1.41 | 1.43 | 1.47 | 1.33 | 1.46 | 1.05 | 0.95 | 0.76 |
| PAT to CFO Conversion(x) | -1 | 8 | 6 | 1.25 | 1.75 | 2.25 | 1.86 | -2.33 | 1.5 | 2.38 | Working Capital Days |
| Receivable Days | 68 | 84 | 63 | 72 | 66 | 60 | 44 | 75 | 90 | 88 |
| Inventory Days | 71 | 61 | 28 | 13 | 19 | 31 | 22 | 24 | 55 | 68 |
| Payable Days | 62 | 71 | 69 | 76 | 67 | 74 | 67 | 59 | 84 | 122 |
Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.
Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.
Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others. Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.
Products
APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.
Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.
Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and 5-Bromo Phthalide
Milestones
1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.
1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).
2004-Company received ISO 9001:2000 certification.
2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).
2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.
Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
